膜杰作
Star Staining
分子别名（Synonym）
LYPD1,Ly6/PLAUR domain-containing protein 1,FLJ41033,LY6/PLAUR domain containing 1,LYPDC1,PHTS,Putative HeLa tumor suppressor
表达区间及表达系统（Source）
Biotinylated Human LYPD1 Protein, His,Avitag (LY1-H82E6) is expressed from human 293 cells (HEK293). It contains AA Leu 21 - Gly 115 (Accession # Q8N2G4-1).
Request for sequence
蛋白结构（Molecular Characterization）
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™)
The protein has a calculated MW of 14.1 kDa. The protein migrates as 18-22 kDa and 35-55 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
标记（Labeling）
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
蛋白标记度（Protein Ratio）
Passed as determined by the HABA assay / binding ELISA.
内毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
纯度（Purity）
>90% as determined by SDS-PAGE.
制剂（Formulation）
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
电泳（SDS-PAGE）
Biotinylated Human LYPD1 Protein, His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
活性（Bioactivity）-ELISA
Immobilized Biotinylated Human LYPD1 Protein, His,Avitag (Cat. No. LY1-H82E6) at 1 μg/mL (100 μL/well) on streptavidin precoated (0.5 μg/well) plate can bind Anti-LYPD1 antibody with a linear range of 0.008-0.125 μg/mL (QC tested).
Protocol
背景（Background）
Believed to act as a modulator of nicotinic acetylcholine receptors (nAChRs) activity. In vitro increases receptor desensitization and decreases affinity for ACh of alpha-4:beta-2-containing nAChRs. May play a role in the intracellular trafficking of alpha-4:beta-2 and alpha-7-containing nAChRs and may inhibit their expression at the cell surface. May be involved in the control of anxiety.
